sur Biomind Labs Inc. (CVE:BMND.NE)
Biomind Labs to List on Canadian Securities Exchange
Biomind Labs Inc., a clinical-stage biopharmaceutical company, announced its approval to list common shares on the Canadian Securities Exchange (CSE). Trading is set to begin on August 11, 2026, under the symbol "BMND". This change follows the company's decision to delist from Cboe Canada, effective August 10, 2026.
Shareholders need not take action regarding this transition, as the OTC Pink listing remains unaffected. The company expressed gratitude to Cboe Canada for its support over the past five years. The move to the CSE marks a new chapter for Biomind, aligning with its ongoing business development and investment opportunities.
Biomind continues to focus on neuroscience and biomedical research to create novel pharmaceutical solutions addressing central nervous system conditions. Their strategy emphasizes rigorous clinical validation.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biomind Labs Inc.